CEO Jaeyoung Shin Leads ORGANOPlus to Redefine Drug Development with Human Organoid Chip Platforms

ORGANOPlus, founded by CEO Jaeyoung Shin, is pioneering organoid chip platforms that replicate complex human microenvironments with unmatched precision. Its flagship technologies—VILLIORGAN™ (gut organoid chip) and CANORGAN™ (tumor microenvironment chip)—enable drug efficacy and safety testing in human-relevant systems, offering an ethical and innovative alternative to animal models. Under Shin’s leadership, the company aims to transform preclinical research and become a global leader in next-generation drug development.